Daiki Kumaki1, Yukio Nakamura1, Noriko Sakai2, Tomoki Kosho1,3, Akinori Nakamura1,4, Shinichi Hirabayashi2, Takako Suzuki1, Mikio Kamimura5, Hiroyuki Kato1. 1. Departments of Orthopaedic Surgery (D.K., Y.N., T.S., and H.K.) and Medical Genetics (T.K.) and Third Department of Medicine (A.N.), Shinshu University School of Medicine, Matsumoto, Japan. 2. Departments of Orthopaedic Surgery (N.S.) and Child Neurology (S.H.), Nagano Prefectural Children's Hospital, Azumino, Japan. 3. Center for Medical Genetics, Shinshu University Hospital, Matsumoto, Japan. 4. Department of Neurology, Matsumoto Medical Center, National Hospital Organization, Matsumoto, Japan. 5. Center of Osteoporosis and Spinal Disorders, Kamimura Orthopaedic Clinic, Matsumoto, Japan.
Abstract
CASE: We report the case of a 13-year-old boy with Duchenne muscular dystrophy (DMD) who sustained bilateral femoral neck fractures associated with glucocorticoid-induced osteoporosis. Denosumab therapy for 18 months markedly improved the lumbar bone mineral density and the bone turnover markers. No fractures or complications were recorded during the treatment period. CONCLUSION: To the best of our knowledge, this is the first description of denosumab treatment for glucocorticoid-induced osteoporosis in a patient with DMD. The drug merits additional testing as an effective therapy for osteoporosis in patients with DMD.
CASE: We report the case of a 13-year-old boy with Duchenne muscular dystrophy (DMD) who sustained bilateral femoral neck fractures associated with glucocorticoid-induced osteoporosis. Denosumab therapy for 18 months markedly improved the lumbar bone mineral density and the bone turnover markers. No fractures or complications were recorded during the treatment period. CONCLUSION: To the best of our knowledge, this is the first description of denosumab treatment for glucocorticoid-induced osteoporosis in a patient with DMD. The drug merits additional testing as an effective therapy for osteoporosis in patients with DMD.